Drug
Aviptadil clinical trials
Also written Vasoactive Intestinal Peptide.
- studies test it
- 14
- open now
- 0
- in phase 3
- 4
- first study started
- 1998
How studies write it
Studies that test it under each name
Studies by the year they started
14 studies that test it; most in 2021 (6)
| Year | Studies |
|---|---|
| 1998 | 1 |
| 2003 | 1 |
| 2004 | 1 |
| 2011 | 1 |
| 2019 | 1 |
| 2020 | 3 |
| 2021 | 6 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
- Phase 2
- 4
- Phase 3
- 4
- No phase
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 3 · Other 11
Danish Headache Center (3) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · TFF Pharmaceuticals, Inc. (2) · APR Applied Pharma Research s.a. (2) · QuantumLeap Healthcare Collaborative (1) · Centurion Pharma (1) · Stony Brook University (1) · Glostrup University Hospital, Copenhagen (1)
Often tested with
Tested in the same studies.
Remdesivir (2) · Imatinib (1) · Dexamethasone (1) · Cenicriviroc (1) · Icatibant (1) · Apremilast (1) · Dornase alfa (1) · Celecoxib (1)
Studies
Open first, then newest update. How each study uses aviptadil is read from its arms, and is right about nine times in ten.
Testing it · 14
- Inhaled ZYESAMI (Aviptadil Acetate) for Treatment of Severe COVID-19WithdrawnPhase 3APR Applied Pharma Research s.a.NCT05137795Written as ZYESAMI™ (aviptadil acetate)
- I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill PatientsActive, not recruitingPhase 2QuantumLeap Healthcare CollaborativeNCT04488081Written as Aviptadil
- ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19CompletedPhase 3National Institute of Allergy and Infectious Diseases (NIAID)NCT04843761Written as Aviptadil
- Aviptadil for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)CompletedPhase 3National Institute of Allergy and Infectious Diseases (NIAID)NCT06729606Written as Aviptadil
- Inhaled Aviptadil for the Treatment of COVID-19 in Patients at High Risk for ARDSTerminatedPhase 2Prof. Dr. Jörg LeuppiNCT04536350Written as Aviptadil 67μg
- A Clinical Study Evaluating Inhaled Aviptadil on COVID-19CompletedPhase 2Centurion PharmaNCT04844580Written as Inhaled Aviptadil
- Inhaled ZYESAMI™ (Aviptadil Acetate) for the Treatment of Severe COVID-19TerminatedPhase 2/3APR Applied Pharma Research s.a.NCT04360096Written as ZYESAMI™ (aviptadil acetate)
- Phase I Study of Vasoactive Intestinal Peptide in Patients With Acute Respiratory Distress Syndrome and SepsisCompletedPhase 1Stony Brook UniversityNCT00004494Written as vasoactive intestinal peptide
- Pharmacokinetic Profile of Voriconazole Inhalation Powder in Adult Subjects With AsthmaCompletedPhase 1TFF Pharmaceuticals, Inc.NCT04576325Written as Voriconazole Inhalation Powder
- Single Ascending Dose and Multiple Ascending Dose Study of Voriconazole Inhalation Powder in Healthy Adult SubjectsCompletedPhase 1TFF Pharmaceuticals, Inc.NCT04872231Written as Voriconazole Inhalation Powder
- The Effects of a Long-lasting Infusion of Vasoactive Intestinal Peptide (VIP) in Episodic Migraine PatientsCompletedNot applicableDanish Headache CenterNCT04260035Written as Vasoactive Intestinal Polypeptide (VIP)
- Effect of PACAP38/VIP on Migraineurs Measured by Magnetic ResonanceCompletedNot applicableGlostrup University Hospital, CopenhagenNCT01471990Written as Vasoactive Intestinal Peptide
- Hemodynamic and Headache-Inducing Effect of Intravenous Vasoactive Intestinal Peptide in MigraineursCompletedNot applicableDanish Headache CenterNCT00272896Written as Vasoactive intestinal peptide
- Experimental Headache Induced by Vasoactive Intestinal PolypeptideCompletedNot applicableDanish Headache CenterNCT00255320Written as VIP
Codes
What other systems call aviptadil · ClinicalTrials.gg INT004389
- MeSH (NLM) C438273aviptadilOne source NLM
- UNII (FDA) A67JUW790CAVIPTADILConfirmed FDA, NLM, Wikidata
- RxNorm 1942960One source Wikidata
- Wikidata Q4828930aviptadilConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C171932AviptadilOne source FDA
- DrugBank DB06260One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C438273 | aviptadil | One source NLM |
| UNII (FDA) | A67JUW790C | AVIPTADIL | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1942960 | — | One source Wikidata |
| Wikidata | Q4828930 | aviptadil | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C171932 | Aviptadil | One source FDA |
| DrugBank | DB06260 | — | One source Wikidata |
Also registered as aviptadil acetate (UNII K24S5TZM78) and vasoactive intestinal peptide (UNII 6J2WVD66KR · RxNorm 1942960).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.